<DOC>
	<DOC>NCT00620464</DOC>
	<brief_summary>The primary purpose of this study is to demonstrate the bioequivalence of IMPLANON and Radiopaque IMPLANON.</brief_summary>
	<brief_title>A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720)</brief_title>
	<detailed_description />
	<mesh_term>Etonogestrel</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<criteria>At least 18 but not older than 40 years of age at the time of screening Good physical and mental health Regular cycles with a usual length between 24 and 35 days Body mass index ≥ 18 and ≤ 29 Willing to give informed consent in writing Contraindications: known or suspected pregnancy active venous thromboembolic disorder (e.g. deep vein thrombosis,pulmonary embolism) presence or history of severe hepatic disease as long as liver function values have not returned to normal malignancy or premalignancy, if sex steroidinfluenced undiagnosed vaginal bleeding hypersensitivity to any of the components of Implanon/Radiopaque Implanon Hypertension, i.e. systolic blood pressure &gt;140 mmHg and/or diastolic blood pressure &gt; 90 mmHg. A history during pregnancy or during previous use of sex steroids of: jaundice and/or severe pruritus related to cholestasis; gallstone formation; porphyria; systemic lupus erythematosus; haemolytic uraemic syndrome; Sydenham's chorea; herpes gestationis; otosclerosisrelated hearing loss Present use or use during 2 months prior to the start of Implanon/Radiopaque Implanon of one of the following drugs: phenytoin, phenobarbital, primidone, carbamazepine, rifampicin, oxcarbazepine, topiramate, felbamate, ritonavir, nelfinavir, griseofulvin or the herbal remedy St John's wort. Administration of investigational drugs within 2 months prior to the start of Implanon/Radiopaque Implanon</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>